ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, announced that Chief Executive Officer Jordan R. Plews, PhD has…
Read More »NASDAQ: ELAB
ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, reported its financial results for the first quarter ended March…
Read More »
ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, has made significant strides of late with the launch of…
Read More »
The agreement adds two drug candidates to the company’s product pipeline, “EL-22”, a clinical-stage engineered probiotic expressing myostatin, and “EL-32”,…
Read More »
The company also reported record Q4 2023 revenue of $698,591, up 403% over the previous quarter. Elevai Labs Inc. (NASDAQ:…
Read More »
Elevai Labs (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today announced the closing of its previously announced…
Read More »
Shares of Elevai Labs have been approved for listing on the NASDAQ and Will Commence Trading on November 21, 2023,…
Read More »